Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.

Martorana F, Vigneri P, Manzella L, Tirrò E, Soto Parra HJ.

Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0596. [Epub ahead of print]

PMID:
31916463
2.

Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform.

Stella S, Massimino M, Tirrò E, Vitale SR, Accurso V, Puma A, Pennisi MS, DI Gregorio S, Romano C, DI Raimondo F, Siragusa S, Manzella L.

Anticancer Res. 2019 Dec;39(12):6965-6971. doi: 10.21873/anticanres.13918.

PMID:
31810968
3.

Combined use of sonographic and elastosonographic parameters can improve the diagnostic accuracy in thyroid nodules at risk of malignancy at cytological examination.

Marturano I, Russo M, Malandrino P, Buscema M, La Rosa GL, Spadaro A, Manzella L, Sciacca L, L'abbate L, Rizzo L.

Minerva Endocrinol. 2019 Oct 11. doi: 10.23736/S0391-1977.19.02945-6. [Epub ahead of print]

PMID:
31625708
4.

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.

Tirrò E, Martorana F, Romano C, Vitale SR, Motta G, Di Gregorio S, Massimino M, Pennisi MS, Stella S, Puma A, Gianì F, Russo M, Manzella L, Vigneri P.

Genes (Basel). 2019 Sep 13;10(9). pii: E709. doi: 10.3390/genes10090709. Review.

5.

Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.

Stella S, Tirró E, Massimino M, Vitale SR, Russo S, Pennisi MS, Puma A, Romano C, DI Gregorio S, Innao V, Stagno F, DI Raimondo F, Musolino C, Manzella L.

In Vivo. 2019 Sep-Oct;33(5):1593-1598. doi: 10.21873/invivo.11641.

6.

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.

Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P.

Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019.

7.

Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.

Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, Di Raimondo F, Manzella L.

Oncol Lett. 2019 Sep;18(3):2648-2653. doi: 10.3892/ol.2019.10558. Epub 2019 Jul 4.

8.

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.

Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P.

Int J Mol Sci. 2019 Jul 2;20(13). pii: E3258. doi: 10.3390/ijms20133258. Review.

9.

Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.

Massimino M, Stella S, Tirrò E, Consoli ML, Pennisi MS, Puma A, Vitale SR, Romano C, Zammit V, Stagno F, DI Raimondo F, Manzella L.

Anticancer Res. 2019 Jul;39(7):3949-3954. doi: 10.21873/anticanres.13548.

PMID:
31262926
10.

Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22).

Tirrò E, Massimino M, Stella S, Zammit V, Consoli ML, Pennisi MS, Vitale SR, Romano C, Pirosa MC, Martino E, DI Gregorio S, Puma A, DI Raimondo F, Manzella L, Stagno F.

Anticancer Res. 2019 Jul;39(7):3893-3899. doi: 10.21873/anticanres.13540.

PMID:
31262918
11.

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.

Int J Mol Sci. 2019 May 6;20(9). pii: E2226. doi: 10.3390/ijms20092226.

12.

Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report.

Tirrò E, Stella S, Massimino M, Zammit V, Pennisi MS, Vitale SR, Romano C, Di Gregorio S, Puma A, Di Raimondo F, Stagno F, Manzella L.

Acta Haematol. 2019;141(4):261-267. doi: 10.1159/000496821. Epub 2019 Apr 9.

PMID:
30965317
13.

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.

Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

14.

Short-term adverse effects of anticancer drugs in patients with type 2 diabetes.

Milluzzo A, Tumminia A, Vella V, Gianì F, Manzella L, Frittitta L, Belfiore A, Vigneri R, Sciacca L.

J Chemother. 2019 May;31(3):150-159. doi: 10.1080/1120009X.2019.1572297. Epub 2019 Feb 10.

PMID:
30739575
15.

B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.

Stella S, Massimino M, Tirrò E, Vitale SR, Scalise L, Leotta S, Pennisi MS, Puma A, Romano C, Stagno F, Sapienza G, Milone G, Manzella L.

Anticancer Res. 2019 Jan;39(1):431-435. doi: 10.21873/anticanres.13130.

PMID:
30591491
16.

Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.

Massimino M, Tirrò E, Stella S, Frasca F, Vella V, Sciacca L, Pennisi MS, Vitale SR, Puma A, Romano C, Manzella L.

Anticancer Res. 2018 Dec;38(12):6653-6662. doi: 10.21873/anticanres.13032.

PMID:
30504373
17.

Long-acting insulin analogs and cancer.

Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, Belfiore A, Vigneri R.

Nutr Metab Cardiovasc Dis. 2018 May;28(5):436-443. doi: 10.1016/j.numecd.2018.02.010. Epub 2018 Feb 24. Review.

PMID:
29609864
18.

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P.

Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1. Review.

19.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

20.

New Insights in Thyroid Cancer and p53 Family Proteins.

Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, Puma A, Tavarelli M, Vigneri P.

Int J Mol Sci. 2017 Jun 21;18(6). pii: E1325. doi: 10.3390/ijms18061325. Review.

21.

Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia.

Manzella L, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Vitale SR, Vigneri P.

Curr Cancer Drug Targets. 2016;16(7):594-605. Review.

PMID:
26728039
22.

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Vigneri P, Martorana F, Manzella L, Stella S.

Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Review.

PMID:
26638920
23.

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy.

Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L.

Front Oncol. 2015 Oct 15;5:230. doi: 10.3389/fonc.2015.00230. eCollection 2015. Review.

24.

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.

Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P.

Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20.

PMID:
24445143
25.

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.

Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG.

FASEB J. 2014 Mar;28(3):1221-36. doi: 10.1096/fj.13-236992. Epub 2013 Dec 2.

PMID:
24297701
26.

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.

Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P.

Mol Cancer Ther. 2013 Jun;12(6):1085-98. doi: 10.1158/1535-7163.MCT-12-0550. Epub 2013 Mar 27.

27.

IRF5 promotes the proliferation of human thyroid cancer cells.

Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L.

Mol Cancer. 2012 Apr 16;11:21. doi: 10.1186/1476-4598-11-21.

28.

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.

Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F.

Acta Haematol. 2012;127(1):7-9. doi: 10.1159/000330607. Epub 2011 Oct 5. No abstract available.

PMID:
21986290
29.

Transcriptional patterns in both host and bacterium underlie a daily rhythm of anatomical and metabolic change in a beneficial symbiosis.

Wier AM, Nyholm SV, Mandel MJ, Massengo-Tiassé RP, Schaefer AL, Koroleva I, Splinter-Bondurant S, Brown B, Manzella L, Snir E, Almabrazi H, Scheetz TE, Bonaldo Mde F, Casavant TL, Soares MB, Cronan JE, Reed JL, Ruby EG, McFall-Ngai MJ.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2259-64. doi: 10.1073/pnas.0909712107. Epub 2010 Jan 19.

30.

Effects of colonization, luminescence, and autoinducer on host transcription during development of the squid-vibrio association.

Chun CK, Troll JV, Koroleva I, Brown B, Manzella L, Snir E, Almabrazi H, Scheetz TE, Bonaldo Mde F, Casavant TL, Soares MB, Ruby EG, McFall-Ngai MJ.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11323-8. doi: 10.1073/pnas.0802369105. Epub 2008 Aug 5.

31.

Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.

Buffa P, Manzella L, Consoli ML, Messina A, Vigneri P.

Proteins. 2007 Apr 1;67(1):1-11.

PMID:
17211892
32.

The PU.1 transcription factor induces cyclin D2 expression in U937 cells.

Vicari L, Eramo A, Manzella L, Malaguarnera L, Iannolo G, Gulisano M, De Maria R, Messina A, Vigneri P.

Leukemia. 2006 Dec;20(12):2208-10. Epub 2006 Oct 19. No abstract available.

PMID:
17051239
33.

Robust semiparametric microarray normalization and significance analysis.

Ma S, Kosorok MR, Huang J, Xie H, Manzella L, Soares MB.

Biometrics. 2006 Jun;62(2):555-61.

PMID:
16918920
34.

Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.

Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P.

Cancer Res. 2006 Apr 15;66(8):4263-72.

35.

Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity.

Malaguarnera L, Pilastro MR, Vicari L, Dimarco R, Manzella L, Palumbo G, Messina A.

Cancer Invest. 2005;23(5):404-12.

PMID:
16193640
36.

A robust two-way semi-linear model for normalization of cDNA microarray data.

Wang D, Huang J, Xie H, Manzella L, Soares MB.

BMC Bioinformatics. 2005 Jan 21;6:14.

37.

Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis.

Conte E, Manzella L, Zeuner A, Cocchiaro G, Conticello C, Zammataro L, Messina CG, De Maria R, Messina A.

Cell Death Differ. 2003 May;10(5):615-7. No abstract available.

38.

Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes.

Luporini SM, Bendit I, Manhani R, Bracco OL, Manzella L, Giannella-Neto D.

J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):357-63.

PMID:
11563770
39.

The interferon regulatory factors 1 and 2 bind to a segment of the human c-myb first intron: possible role in the regulation of c-myb expression.

Manzella L, Gualdi R, Perrotti D, Nicolaides NC, Girlando G, Giuffrida MA, Messina A, Calabretta B.

Exp Cell Res. 2000 Apr 10;256(1):248-56.

PMID:
10739671
40.

Role of interferon regulatory factor 1 in monocyte/macrophage differentiation.

Manzella L, Conte E, Cocchiaro G, Guarniera E, Sciacca B, Bonaiuto C, Stagno F, Messina A.

Eur J Immunol. 1999 Sep;29(9):3009-16.

41.
42.
43.
44.

Positive autoregulation of c-myb expression via Myb binding sites in the 5' flanking region of the human c-myb gene.

Nicolaides NC, Gualdi R, Casadevall C, Manzella L, Calabretta B.

Mol Cell Biol. 1991 Dec;11(12):6166-76.

45.

Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.

Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B.

Science. 1991 Aug 2;253(5019):562-5.

PMID:
1857987

Supplemental Content

Loading ...
Support Center